Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIT-013 150 mg phase 1 trial
NL-OMON61164Phase 1Completed
- Sponsor
- Citryll
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of CIT013 in autoimmune inflammatory diseases, sponsored by Citryll. Started May 2026; status: completed.
02
Drugs
CIT013
03
Conditions
autoimmune inflammatory diseases
Beyond the preview
Go deeper on NL-OMON61164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61164.